Dr. Scott Whitcup is founder and CEO of Akrivista and Whitecap Biosciences, two companies focused on the development and commercialization of novel therapies in ophthalmology and dermatology.

Previously, Dr. Whitcup was the Executive Vice President, R&D and Chief Scientific Officer at Allergan where he lead the discovery and global development of both pharmaceutical products and medical devices in therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, and surgical obesity.

Key product approvals included Botox® for chronic migraine, upper limb spasticity, and crow’s feet lines; Restasis® for dry eye; Alphagan® Lumigan®, and Combigan® for glaucoma; Ozurdex® for diabetic macular edema; and Juvederm Voluma® for facial aesthetics. Dr. Whitcup was in charge of the global medical affairs organization and involved in the commercial launch of more than a dozen pharmaceutical and medical device products globally.

He also built the technology assessment group to support Allergan’s business development and M&A activities.

Before Allergan, Dr. Whitcup was the Clinical Director at the National Eye Institute at the NIH, where he led its intramural clinical research program, headed an immunology lab in the Clinical Branch, and Chaired the NIH Medical Executive Committee.

Dr. Whitcup has a B.A. in Neurobiology and Behavior from Cornell University and an M.D from Cornell University Medical College. He has completed a residency in Internal Medicine at UCLA, a residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary, and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute, National Institutes of Health.

He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in CA, and is on the Clinical Faculty of the Department of Ophthalmology, at the Jules Stein Eye Institute, David Geffen School of Medicine at UCLA. Dr. Whitcup has published more than 250 scientific articles and co-authored a leading textbook on uveitis and ocular immunology.

He has 17 issued and 20 pending US patents and over 300 issued and pending international patents. Dr. Whitcup serves on the Board of Semnur Pharmaceuticals and has served on the Boards of Avanir Pharmaceuticals and Questcor Pharmaceuticals.